Oprozomib, pomalidomide, and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma-Reference-Cited by-同舟云学术

Oprozomib, pomalidomide, and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma

Published:2019-09 Issue:9 Volume:19 Page:570-578.e1
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Shah Jatin,Usmani Saad,Stadtmauer Edward A.,Rifkin Robert M.,Berenson James R.,Berdeja Jesus G.,Lyons Roger M.,Klippel Zandra,Chang Yu-Lin,Niesvizky Ruben

Funder

Onyx Pharmaceuticals

Amgen

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference23 articles.

1. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma;Cavo;Blood,2012

2. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study

3. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial;Durie;Lancet,2017

4. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma;Moreau;N Engl J Med,2016

5. ASPIRE Investigators. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma;Stewart;N Engl J Med,2015

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phase I study of TQB3602, an oral proteasome inhibitor, in relapsed and refractory multiple myeloma;Cancer Medicine;2024-07

2. Development of Proteasome Inhibitors for Cancer Therapy;International Journal of Drug Discovery and Pharmacology;2024-03-18

3. Epstein–Barr Virus: Human Interactome Reveals New Molecular Insights into Viral Pathogenesis for Potential Therapeutics and Antiviral Drug Discovery;OMICS: A Journal of Integrative Biology;2024-01-01

4. Exploiting the potential of the ubiquitin-proteasome system in overcoming tyrosine kinase inhibitor resistance in chronic myeloid leukemia;Genes & Diseases;2023-10

5. A Reliable and Effective UPLC-MS/MS Method for the Determination of Oprozomib in Rat Plasma;Journal of Analytical Methods in Chemistry;2023-07-11